<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882320</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0044</org_study_id>
    <nct_id>NCT03882320</nct_id>
  </id_info>
  <brief_title>Medico-economic Evaluation of Sublingual PCA (Zalviso) Versus Oxycodone-PCA in the Management of Postoperative Pain.</brief_title>
  <acronym>MEZO</acronym>
  <official_title>Medico-economic Evaluation of Sublingual PCA (Zalviso) Versus Oxycodone-PCA in the Management of Postoperative Pain. ''MEZO''</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 230 million surgical operations are been realized all over the world every year. A
      surgical intervention can cause postoperative acute pain. The management of postoperative
      acute pain is multimodal and the use of patient-controlled analgesia (PCA) is often a part of
      this Pain-Management.

      Intravenous PCA has established itself as a therapeutic concept and constitutes the reference
      treatment for the management of postoperative acute pain for the first 48 hours. The PCA
      offers patients autonomy in managing their pain with the intravenous delivery of morphine on
      demand.

      Since 2017 PCA Zalviso is marketed. It allows the sublingual administration of sufentanil and
      it does not require venous access. It seems interesting to allow the early rehabilitation of
      patients who are no longer limited in their movements by an infusion. However, its
      acquisition cost appears to be higher than that of the intravenous PCA. In order to verify
      this hypothesis, the investigators propose to compare the set of costs associated with the
      use of sublingual PCA with those of intravenous PCA in the management of acute postoperative
      pain (less than 72 hours) in the context of patients benefiting from the placement of a total
      knee arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Costs of each Intravenous Patient Controlled Analgesia (PCA)</measure>
    <time_frame>until 72 hours after knee arthroplasty</time_frame>
    <description>Comparison of costs associated with the use of sublingual PCA to those of intravenous PCA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>until 72 hours after knee arthroplasty</time_frame>
    <description>Length of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency of acute postoperative pain management</measure>
    <time_frame>until 72 hours after knee arthroplasty</time_frame>
    <description>Pain intensity is measured with numeric score (scale 0 to 10) (10 is the highest pain intensity; 0 is the score for the absence of pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global satisfaction of the patient</measure>
    <time_frame>until 72 hours after knee arthroplasty</time_frame>
    <description>Global satisfaction of the patient is measured with &quot; Echelle Visuelle Analogique&quot; EVA score (scale 0 to 10; score 0= no pain; score 10 = pain with the highest intensity)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Sublingual Patient Controlled Analgesia (PCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sufentanil Sublingual Patient Controlled Analgesia (PCA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Patient Controlled Analgesia (PCA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone Intravenous Patient Controlled Analgesia (PCA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Patient Controlled Analgesia (PCA)</intervention_name>
    <description>Patient Controlled Analgesia (PCA)</description>
    <arm_group_label>Intravenous Patient Controlled Analgesia (PCA)</arm_group_label>
    <arm_group_label>Sublingual Patient Controlled Analgesia (PCA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults

          -  patients able to express consent

          -  signed written informed consent form

          -  patient covered by national health insurance

          -  patient undergoing total knee arthroplasty and requiring postoperative analgesia with
             the use of a PCA (patient controlled analgesia)

        Exclusion Criteria:

          -  minors

          -  obstruction to participate

          -  patient non covered by national health insurance

          -  patient requiring a stay in intensive care immediately after the surgery

          -  patient unable to use a PCA a assessed by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre NTOUBA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandrine THOMAS SORIOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre CORIAT, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpêtrière Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre NTOUBA, MD</last_name>
    <phone>(33)322087947</phone>
    <email>ntouba.alexandre@chu-amiens.fr</email>
  </overall_contact>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sublingual Patient Controlled Analgesia (PCA)</keyword>
  <keyword>Intravenous Patient Controlled Analgesia (PCA)</keyword>
  <keyword>Patient Controlled Analgesia (PCA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

